Literature DB >> 23679234

Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.

Magdalena Głowala-Kosińska1, Agata Chwieduk, Jarosław Nieckula, Maria Saduś-Wojciechowska, Sebastian Grosicki, Aleksandra Rusin, Elżbieta Nowara, Sebastian Giebel.   

Abstract

Regulatory T (Treg) cells are essential for maintaining immune tolerance. High Treg frequencies have been reported in peripheral blood and tissue samples of patients with solid tumors while their role in lymphomas, including diffuse large B-cell lymphoma (DLBCL) has not been clearly established. In this study, we analyzed the circulating Treg numbers in 27 patients with newly diagnosed DLBCL and 17 healthy individuals. Tregs were detected by flow cytometry based on CD4(+) CD25(high) FoxP3(+) phenotype. In addition, the expression of CD45RA, HLA-DR, CD62L, CD39, and CTLA4 was analyzed. The number of circulating Treg cells was lower in patients with DLBCL than in healthy controls: median 23 (range, 4-107)/μL vs. 41 (19-104)/μL (P = 0.04). In particular, the number of Tregs expressing CD45RA (naïve Tregs), HLA-DR (marker of activation), and CD62L (L-selectin) was decreased in the DLBCL group. Lower (below median) number of circulating Tregs was associated with reduced chance of achieving complete remission (29% vs. 69%, P = 0.05) and reduced probability of even-free survival (24% vs. 84% at 1 yr, P = 0.0004), independently on the International Prognostic Index. We conclude that low number of circulating Tregs may be associated with poor prognosis in patients with DLBCL. However, our observations require confirmation in larger patient population.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Treg; diffuse large B-cell lymphoma; prognosis; regulatory T cells

Mesh:

Substances:

Year:  2013        PMID: 23679234     DOI: 10.1111/ejh.12144

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

1.  CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.

Authors:  Carolina Cubillos-Zapata; Raúl Cordoba; José Avendaño-Ortiz; Cristina Arribas-Jiménez; Enrique Hernández-Jiménez; Víctor Toledano; Teresa Villaescusa; Víctor Moreno; Eduardo López-Collazo
Journal:  Oncoimmunology       Date:  2016-09-16       Impact factor: 8.110

2.  Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation.

Authors:  Monika Anna Grygorowicz; Ilona Sara Borycka; Eliza Nowak; Ewa Paszkiewicz-Kozik; Grzegorz Rymkiewicz; Katarzyna Błachnio; Marzena Biernacka; Mateusz Bujko; Jan Walewski; Sergiusz Markowicz
Journal:  Clin Exp Med       Date:  2016-03-10       Impact factor: 3.984

3.  Lkb1 aggravates diffuse large B-cell lymphoma by promoting the function of Treg cells and immune escape.

Authors:  Xiuhua Su; Tao Sun; Meng Li; Yuan Xia; Mingying Li; Dongmei Wang; Fei Lu; Jingjing Ye; Chunyan Ji
Journal:  J Transl Med       Date:  2022-08-19       Impact factor: 8.440

4.  Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Authors:  Yan-Li Li; Kang-Sheng Gu; Yue-Yin Pan; Yang Jiao; Zhi-Min Zhai
Journal:  BMC Cancer       Date:  2014-05-19       Impact factor: 4.430

5.  High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.

Authors:  Sewa Rijal; Johanna Kok; Caitlin Coombes; Lillian Smyth; Jayde Hourigan; Sanjiv Jain; Dipti Talaulikar
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

6.  Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.

Authors:  Carlos Jiménez-Cortegana; Natalia Palazón-Carrión; Alejandro Martin Garcia-Sancho; Esteban Nogales-Fernandez; Fernando Carnicero-González; Eduardo Ríos-Herranz; Fatima de la Cruz-Vicente; Guillermo Rodríguez-García; Rubén Fernández-Álvarez; Antonio Rueda Dominguez; Maria Casanova-Espinosa; Natividad Martínez-Banaclocha; Josep Gumà-Padrò; José Gómez-Codina; Jorge Labrador; Antonio Salar-Silvestre; Delvys Rodriguez-Abreu; Laura Galvez-Carvajal; Mariano Provencio; Margarita Sánchez-Beato; María Guirado-Risueño; Pablo Espejo-García; Marylene Lejeune; Tomás Álvaro; Victor Sánchez-Margalet; Luis de la Cruz-Merino
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.